Xu-Dong Qu

机构：Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital · ORCID：0000-0001-5927-6085

发表论文 52 篇 · 总被引 1339 次 · h-index 20

代表论文

• Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations (2021 · Liver Cancer · 被引 239)
• Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma (2022 · Annals of Surgical Oncology · 被引 75)
• Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study (2022 · BJS Open · 被引 60)
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma (2024 · Nature Communications · 被引 51)
• Hsa_circ_0026134 expression promoted TRIM25- and IGF2BP3-mediated hepatocellular carcinoma cell proliferation and invasion via sponging miR-127-5p (2020 · Bioscience Reports · 被引 45)
• Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2 (2019 · Biochemical and Biophysical Research Communications · 被引 36)